3M (MMM) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered strong adjusted EPS of $1.93, up 39% year-over-year, with robust cash generation and 1.2% organic growth; operational excellence, R&D, and capital deployment remain key priorities.

• Significant transformation underway, including the completed spin-off of the Health Care business (Solventum), restructuring, and planned PFAS exit by 2025.

• CEO and management focus on reinvigorating R&D, commercial excellence, and supply chain optimization.

• Operational execution drove results, with strength in electronics and mixed industrial end-markets, while consumer retail demand remained soft.

Financial highlights

• Q2 2024 net sales: $6.26 billion (down 0.5% year-over-year); adjusted sales: $6.0 billion (up 1.2% organically); adjusted operating margin: 21.6% (up 440 bps); adjusted EPS: $1.93.

• Adjusted free cash flow: $1.2 billion, with 109% conversion; operating cash flow: $1.0 billion.

• Net income from continuing operations: $1.2 billion, or $2.17 per diluted share.

• $800 million returned to shareholders in Q2 via dividends and buybacks.

• Gross margin improved to 42.9% from 40.7% year-over-year.

Outlook and guidance

• Raised full-year 2024 adjusted EPS guidance to $7.00–$7.30 (up 16–21% year-over-year).

• Full-year adjusted operating margin expected up 225–275 bps; organic growth guidance flat to up 2%.

• Full-year pre-tax restructuring charges expected at $250–$300 million.

• No material impact from global minimum tax (OECD Pillar Two) expected in 2024.